Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 477
- 主要终点
- Incidence of myelosuppression (≤150 days)
研究概览
简要总结
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.
详细描述
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. To study the risk factors related to myelosuppression during chemotherapy, and to preliminarily explore the characteristics of myelosuppression caused by combination chemotherapy with platinum.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with non-small cell lung cancer with clear imaging or pathological evidence
- •Using a chemotherapy regimen containing platinum
- •Conducted blood routine and biochemical tests
- •Signed informed consent
排除标准
- •Blood routine and other relevant tests were not performed
- •Suffering from primary bone marrow system disease
- •Other reasons for not meeting the experimental requirements
结局指标
主要结局
Incidence of myelosuppression (≤150 days)
时间窗: The platinum-based regimen was followed by 4 to 6 cycles of chemotherapy (each cycle is 28 days), 4 visits per treatment cycle, and day0, day1, day2-5, day6-21 after chemotherapy were recorded
Myelosuppression was judged according to WHO grading criteria
次要结局
未报告次要终点
研究者
LI YAN
professor
Qianfoshan Hospital